El-Ghandour, A., El-Bendary, A., Shahba, A., Soliman, G. (2019). Study of Serum Betatrophin Level in The Patients of Type 2 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 74(8), 1809-1816. doi: 10.21608/ejhm.2019.28682
Aliaa H. El-Ghandour; Aml S. El-Bendary; Abeer A. Shahba; Ghada A. Soliman. "Study of Serum Betatrophin Level in The Patients of Type 2 Diabetes Mellitus". The Egyptian Journal of Hospital Medicine, 74, 8, 2019, 1809-1816. doi: 10.21608/ejhm.2019.28682
El-Ghandour, A., El-Bendary, A., Shahba, A., Soliman, G. (2019). 'Study of Serum Betatrophin Level in The Patients of Type 2 Diabetes Mellitus', The Egyptian Journal of Hospital Medicine, 74(8), pp. 1809-1816. doi: 10.21608/ejhm.2019.28682
El-Ghandour, A., El-Bendary, A., Shahba, A., Soliman, G. Study of Serum Betatrophin Level in The Patients of Type 2 Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 2019; 74(8): 1809-1816. doi: 10.21608/ejhm.2019.28682
Study of Serum Betatrophin Level in The Patients of Type 2 Diabetes Mellitus
1Department of Clinical Pathology, Faculty of Medicine, Tanta University
2Department of Internal Medicine Faculty of Medicine, Tanta University
Abstract
Background: Type 2 DM is due primarily to lifestyle and genetic factors. A number of lifestyle factors are known to be important to the development of type 2 DM. Betatrophin, also known as angiopoietin-like protein (ANGPTL8), is a circulating protein predominantly produced in the liver and adipose tissue. Betatrophin is induced as a result of insulin resistance. It is reported to modulate pancreatic β-cell mass and glucose homeostasis reflectable on lipid metabolism. Aim of the Study: Evaluation of the role of betatrophin in patients with type 2 diabetes mellitus. Patients and Methods: This clinical study was carried out at Clinical Pathology Department, Tanta University Hospital and included 80 subjects who were divided into two groups: Group 1:40 Patients diagnosed with type 2 diabetes mellitus. Group 2: 40 normal subjects with matched age and sex as a control group. Results: In type 2 diabetes mellitus patients group, serum betatrophin ranged from 25.83 to 860.65 ng/l with a median value of 54.815 ng/l while in control group, betatrophin ranged from 7.5-53.2 ng/l with a madian value of 11.250 ng/l. There was significant statistical difference in betatrophin between the two groups. (P < 0.001). Betatrophin was significantly higher in type 2 diabtes mellitus patients as compared to control group. Conclusion: Circulating betatrophine concentrations were significantly increased in patients with T2 DM and associated with glucose homeostasis and insulin sensitivity. Thus, the level of serum betatrophin has a potential role in detection and pathogenesis of T2DM.